Pharma companies create $1bn fund to save antibiotic researchMore than 20 pharma companies including GlaxoSmithKline, Novartis and Pfizer have joined forces to create a $1 billion Share XPharma companies create $1bn fund to save antibiotic researchhttps://pharmaphorum.com/news/pharma-companies-create-1bn-fund-to-save-antibiotic-research/
Coronavirus pharma news roundup – 10/07/20As coronavirus vaccines and treatments advance rapidly through research and development, the world starts to consider what drugs Share XCoronavirus pharma news roundup – 10/07/20https://pharmaphorum.com/r-d/views-analysis-r-d/coronavirus-pharma-news-roundup-10-07-20/
Kymera Therapeutics begins potential $2bn R&D deal with SanofiUS biotech Kymera Therapeutics has begun a strategic collaboration with Sanofi to develop and market several drugs tackling immune-inflammatory disease, which Share XKymera Therapeutics begins potential $2bn R&D deal with Sanofihttps://pharmaphorum.com/news/kymera-therapeutics-begins-potential-2bn-rd-deal-with-sanofi/
Gilead starts trials of inhaled remdesivir for earlier-stage COVID-19The first healthy volunteers have started to receive doses of Gilead’s inhaled formulation of remdesivir, which it hopes Share XGilead starts trials of inhaled remdesivir for earlier-stage COVID-19https://pharmaphorum.com/news/gilead-starts-trials-of-inhaled-remdesivir-for-earlier-stage-covid-19/
Expanding research capacity into neglected tropical diseasesProfessor Paul Kaye from the University of York, whose research team was recently granted €8 million to help Share XExpanding research capacity into neglected tropical diseaseshttps://pharmaphorum.com/r-d/views-analysis-r-d/expanding-research-capacity-into-neglected-tropical-diseases/
Regeneron begins late-stage trial testing COVID-19 antibody cocktailRegeneron has begun a late-stage clinical trial testing its double “antibody cocktail” as a preventive treatment for COVID-19. Share XRegeneron begins late-stage trial testing COVID-19 antibody cocktailhttps://pharmaphorum.com/news/regeneron-begins-late-stage-trial-testing-covid-19-antibody-cocktail/
UK trial begins testing second-wave COVID-19 drug from US biotech RidgebackThe AGILE programme, which is researching a second wave of COVID-19 therapies in the UK, has begun testing its first potential Share XUK trial begins testing second-wave COVID-19 drug from US biotech Ridgebackhttps://pharmaphorum.com/news/uk-trial-begins-testing-second-wave-covid-19-drug-from-us-biotech-ridgeback/
CureVac claims €75m in EU funding for mRNA COVID-19 vaccineGerman vaccine firm CureVac has been awarded a €75 million loan from the European Investment Bank to boost Share XCureVac claims €75m in EU funding for mRNA COVID-19 vaccinehttps://pharmaphorum.com/news/curevac-claims-e75m-in-eu-funding-for-mrna-covid-19-vaccine/
Idorsia on course to take on Eisai and Merck & Co after latest insomnia phase 3 trial winSwitzerland’s Idorsia says it is on course to file a potential next-generation insomnia drug around the end of this year after a Share XIdorsia on course to take on Eisai and Merck & Co after latest insomnia phase 3 trial winhttps://pharmaphorum.com/news/idorsia-on-course-to-take-on-eisai-and-merck-co-after-latest-insomnia-phase-3-trial-win/
